Inhibited Growth of a Reticulum Cell Sarcoma (M5076) Induced in Vitro and in Vivo by Macrophage-activating Agents

James E Talmadge, I. R. Hart

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The tumor M5076 is highly malignant in vivo; however, in vitro M5076 tumor cells express many of the differentiated characteristics of an Activated macrophage. Recently, we reported that this macrophage tumor (M5076) can be induced to cease cellular division following in vitro exposure to macrophage-activating agents, which we felt was due to the induction of terminal differentiation. In the present study, we report that not all macrophage-activating agents halt the proliferation of M5076 tumor cells in vitro, and we present evidence that the treatment of mice bearing M5076 tumor cells with lipopolysaccharide is a highly effective therapeutic modality. Therapy protocols using multiple injections of lipopolysaccharide are capable of prolonging the survival and reducing the metastatic tumor burden of mice with a large tumor burden at the onset of therapy. This indicates that caution should be exercised in the use of M5076 tumors as a test model for chemotherapeutic agents, since the slightest contamination of an experimental drug with lipopolysaccharide would result in spurious positive results.

Original languageEnglish (US)
Pages (from-to)2446-2451
Number of pages6
JournalCancer Research
Volume44
Issue number6
StatePublished - Jun 1 1984

Fingerprint

Non-Hodgkin's Lymphoma
Macrophages
Growth
Lipopolysaccharides
Neoplasms
Tumor Burden
Drug Contamination
Therapeutics
In Vitro Techniques
Injections

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Inhibited Growth of a Reticulum Cell Sarcoma (M5076) Induced in Vitro and in Vivo by Macrophage-activating Agents. / Talmadge, James E; Hart, I. R.

In: Cancer Research, Vol. 44, No. 6, 01.06.1984, p. 2446-2451.

Research output: Contribution to journalArticle

@article{88cf1c2ed0d846c5af88dfdea2915eb2,
title = "Inhibited Growth of a Reticulum Cell Sarcoma (M5076) Induced in Vitro and in Vivo by Macrophage-activating Agents",
abstract = "The tumor M5076 is highly malignant in vivo; however, in vitro M5076 tumor cells express many of the differentiated characteristics of an Activated macrophage. Recently, we reported that this macrophage tumor (M5076) can be induced to cease cellular division following in vitro exposure to macrophage-activating agents, which we felt was due to the induction of terminal differentiation. In the present study, we report that not all macrophage-activating agents halt the proliferation of M5076 tumor cells in vitro, and we present evidence that the treatment of mice bearing M5076 tumor cells with lipopolysaccharide is a highly effective therapeutic modality. Therapy protocols using multiple injections of lipopolysaccharide are capable of prolonging the survival and reducing the metastatic tumor burden of mice with a large tumor burden at the onset of therapy. This indicates that caution should be exercised in the use of M5076 tumors as a test model for chemotherapeutic agents, since the slightest contamination of an experimental drug with lipopolysaccharide would result in spurious positive results.",
author = "Talmadge, {James E} and Hart, {I. R.}",
year = "1984",
month = "6",
day = "1",
language = "English (US)",
volume = "44",
pages = "2446--2451",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Inhibited Growth of a Reticulum Cell Sarcoma (M5076) Induced in Vitro and in Vivo by Macrophage-activating Agents

AU - Talmadge, James E

AU - Hart, I. R.

PY - 1984/6/1

Y1 - 1984/6/1

N2 - The tumor M5076 is highly malignant in vivo; however, in vitro M5076 tumor cells express many of the differentiated characteristics of an Activated macrophage. Recently, we reported that this macrophage tumor (M5076) can be induced to cease cellular division following in vitro exposure to macrophage-activating agents, which we felt was due to the induction of terminal differentiation. In the present study, we report that not all macrophage-activating agents halt the proliferation of M5076 tumor cells in vitro, and we present evidence that the treatment of mice bearing M5076 tumor cells with lipopolysaccharide is a highly effective therapeutic modality. Therapy protocols using multiple injections of lipopolysaccharide are capable of prolonging the survival and reducing the metastatic tumor burden of mice with a large tumor burden at the onset of therapy. This indicates that caution should be exercised in the use of M5076 tumors as a test model for chemotherapeutic agents, since the slightest contamination of an experimental drug with lipopolysaccharide would result in spurious positive results.

AB - The tumor M5076 is highly malignant in vivo; however, in vitro M5076 tumor cells express many of the differentiated characteristics of an Activated macrophage. Recently, we reported that this macrophage tumor (M5076) can be induced to cease cellular division following in vitro exposure to macrophage-activating agents, which we felt was due to the induction of terminal differentiation. In the present study, we report that not all macrophage-activating agents halt the proliferation of M5076 tumor cells in vitro, and we present evidence that the treatment of mice bearing M5076 tumor cells with lipopolysaccharide is a highly effective therapeutic modality. Therapy protocols using multiple injections of lipopolysaccharide are capable of prolonging the survival and reducing the metastatic tumor burden of mice with a large tumor burden at the onset of therapy. This indicates that caution should be exercised in the use of M5076 tumors as a test model for chemotherapeutic agents, since the slightest contamination of an experimental drug with lipopolysaccharide would result in spurious positive results.

UR - http://www.scopus.com/inward/record.url?scp=0021265117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021265117&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 2446

EP - 2451

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 6

ER -